Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11401256 Dihydroquinolinones for medical treatment

Patent 11401256 was granted and assigned to C4 Therapeutics on August, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

C4 Therapeutics

0

Current Assignee

C4 Therapeutics

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Adrian Britschgi0

Roger Norcross0

Moreno Attilio Wichert0

Fabian Dey0

Eric Andre Kusznir0

Annick Goergler0

Date of Patent

August 2, 2022

0

Patent Application Number

168093450

Date Filed

March 4, 2020

0

Patent Citations

US Patent 10646575 Heterocyclic degronimers for target protein degradation

US Patent 10660968 Spirocyclic degronimers for target protein degradation

Patent Citations Received

US Patent 12091397 Dihydroquinolinones for medical treatment

0

US Patent 11802131 Glutarimides for medical treatment

0

Patent Primary Examiner

0

The present invention provides dihydroquinolinone compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11401256 Dihydroquinolinones for medical treatment

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool